---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-133784"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:46:03.838935+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm Q1 total revenue $33.1M, net loss $0.32/share; extends debt maturities to 2028/2029

## Summary
- Q1 2024 total revenue $33.1M (vs $38.7M Q1 2023); U.S. XPOVIO net product revenue $26.0M (vs $28.3M Q1 2023).
- Net loss $37.4M ($0.32 per share) vs $34.1M ($0.30 per share) in Q1 2023; R&D expenses $35.4M, SG&A $29.5M.
- Reaffirms FY2024 guidance: total revenue $140-160M; XPOVIO net product revenue $100-120M; R&D+SG&A $260-280M.
- Completed refinancing: extended majority of debt maturities to 2028/2029 and amended HCRx royalty, reducing royalty rate from 12.5% to 7.0%.
- Cash, equivalents, restricted cash and investments $149.3M as of March 31, 2024; cash runway expected into end of 2025.

## SEC filing metadata
- accession: 0001193125-24-133784
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/0001193125-24-133784-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/d809399d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-133784
- JSON: https://secwatch.observer/filing/0001193125-24-133784.json
- Plain text: https://secwatch.observer/filing/0001193125-24-133784.txt

## Key facts
- Earnings Releases
  Karyopharm Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $33.1 million. Guidance reaffirmed.
  - Period: the quarter ended March 31, 2024
  - Revenue: $33.1 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Readouts and Potential Approvals from the Company’s Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Achieves First Quarter 2024 Total Revenue of $33.1 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $26.0 Million – – Reaffirms Full Year 2024 Total Revenue Guidance of $140.0 Million to $160.0 Million, Including U.S. XPOVIO
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312524133784/0001193125-24-133784-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.